Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    7674315 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
Conditions: Colorectal Neoplasm;   Hereditary Nonpolyposis
Intervention: Drug: Celecoxib (SC-58635)

Indicates status has not been verified in more than two years